About HLA class I histocompatibility antigen, B alpha chain
HLA class I histocompatibility antigen, B alpha chain (HLA-B) is a protein
from Homo sapiens identified by UniProt accession
P01889, 362 residues long.
MolForge cross-references it against 0 known binders and
786 disease associations.
Target properties
| Protein name | HLA class I histocompatibility antigen, B alpha chain |
|---|
| UniProt accession | P01889 |
|---|
| Gene | HLA-B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 362 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (786)
Diseases linked to this target (Open Targets).
- COVID-19 · score 0.48
- neurodegenerative disease · score 0.47
- blood protein measurement · score 0.44
- asthma · score 0.42
- diffuse large B-cell lymphoma · score 0.40
- low density lipoprotein cholesterol measurement · score 0.40
- Stevens-Johnson syndrome · score 0.38
- allergic disease · score 0.37
- spondyloarthropathy · score 0.37
- HIV-1 infection · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P01889-F1 | alphafold | PREDICTED | 88.08 | — |
Amino-acid sequence (362 residues)
MLVMAPRTVL LLLSAALALT ETWAGSHSMR YFYTSVSRPG RGEPRFISVG YVDDTQFVRF DSDAASPREE PRAPWIEQEG PEYWDRNTQI YKAQAQTDRE SLRNLRGYYN QSEAGSHTLQ SMYGCDVGPD GRLLRGHDQY AYDGKDYIAL NEDLRSWTAA DTAAQITQRK WEAAREAEQR RAYLEGECVE WLRRYLENGK DKLERADPPK THVTHHPISD HEATLRCWAL GFYPAEITLT WQRDGEDQTQ DTELVETRPA GDRTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEP SSQSTVPIVG IVAGLAVLAV VVIGAVVAAV MCRRKSSGGK GGSYSQAACS DSAQGSDVSL TA
Explore HLA class I histocompatibility antigen, B alpha chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets